BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 29464446)

  • 1. Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important.
    Jin XF; Spampatti MP; Spitzweg C; Auernhammer CJ
    Rev Endocr Metab Disord; 2018 Jun; 19(2):145-158. PubMed ID: 29464446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A tale of two tumors: treating pancreatic and extrapancreatic neuroendocrine tumors.
    Halperin DM; Kulke MH; Yao JC
    Annu Rev Med; 2015; 66():1-16. PubMed ID: 25341008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of gastroentero-pancreatic neuroendocrine tumors (GEP-NETs).
    Desai KK; Khan MS; Toumpanakis C; Caplin ME
    Minerva Gastroenterol Dietol; 2009 Dec; 55(4):425-43. PubMed ID: 19942827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Neuroendocrine tumors of the gastrointestinal tract].
    Arnold C
    Praxis (Bern 1994); 2007 Jan; 96(1-2):19-28. PubMed ID: 17256557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes.
    Hofland J; Falconi M; Christ E; Castaño JP; Faggiano A; Lamarca A; Perren A; Petrucci S; Prasad V; Ruszniewski P; Thirlwell C; Vullierme MP; Welin S; Bartsch DK
    J Neuroendocrinol; 2023 Aug; 35(8):e13318. PubMed ID: 37578384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEPNETs): A Review.
    Pasricha G; Padhi P; Daboul N; Monga DK
    Clin Ther; 2017 Nov; 39(11):2146-2157. PubMed ID: 29173655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastroenteropancreatic Neuroendocrine Tumors.
    Cives M; Strosberg JR
    CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion.
    Yoo C; Oh CR; Kim ST; Bae WK; Choi HJ; Oh DY; Lee MA; Ryoo BY
    Cancer Res Treat; 2021 Apr; 53(2):291-300. PubMed ID: 33421978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Neuroendocrine tumors of the digestive system].
    Prónai L; Rácz K; Tulassay Z
    Orv Hetil; 2002 May; 143(19 Suppl):1081-6. PubMed ID: 12063866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
    Phan AT; Kunz PL; Reidy-Lagunes DL
    Clin Adv Hematol Oncol; 2015 May; 13(5 Suppl 5):1-18; quiz 1 p following 18. PubMed ID: 26430956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of Gastroenteropancreatic Neuroendocrine Tumors.
    Perez K; Chan J
    Surg Pathol Clin; 2019 Dec; 12(4):1045-1053. PubMed ID: 31672293
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.
    Jiménez-Fonseca P; Carmona-Bayonas A; Martín-Pérez E; Crespo G; Serrano R; Llanos M; Villabona C; García-Carbonero R; Aller J; Capdevila J; Grande E;
    Cancer Metastasis Rev; 2015 Sep; 34(3):381-400. PubMed ID: 26245646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Diagnostics and treatment in functional pancreatic neuroendocrine tumours].
    Müssig K; Dudziak K; Horger M; Anlauf M; Goretzki PE
    Dtsch Med Wochenschr; 2011 Jun; 136(24):1319-30. PubMed ID: 21656454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors.
    Cloyd JM; Konda B; Shah MH; Pawlik TM
    Expert Rev Clin Pharmacol; 2019 Feb; 12(2):101-108. PubMed ID: 30582383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours.
    Dimitriadis GK; Weickert MO; Randeva HS; Kaltsas G; Grossman A
    Endocr Relat Cancer; 2016 Sep; 23(9):R423-36. PubMed ID: 27461388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New and emerging systemic therapy options for well-differentiated gastroenteropancreatic neuroendocrine tumors.
    Scoville SD; Cloyd JM; Pawlik TM
    Expert Opin Pharmacother; 2020 Feb; 21(2):183-191. PubMed ID: 31760823
    [No Abstract]   [Full Text] [Related]  

  • 17. [Endocrine-active gastrointestinal tumors: are there any new therapeutic possibilities?].
    Marbet UA; Kraenzlin M; Gyr K; Stalder GA
    Dtsch Med Wochenschr; 1986 Jul; 111(28-29):1120-3. PubMed ID: 2426077
    [No Abstract]   [Full Text] [Related]  

  • 18. The State of Peptide Receptor Radionuclide Therapy and Its Sequencing among Current Therapeutic Options for Gastroenteropancreatic Neuroendocrine Tumors.
    Raymond LM; Korzun T; Kardosh A; Kolbeck KJ; Pommier R; Mittra ES
    Neuroendocrinology; 2021; 111(11):1086-1098. PubMed ID: 33744879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status of Interventional Radiology in the management of Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NETs).
    Orgera G; Krokidis M; Cappucci M; Gourtsoyianni S; Tipaldi MA; Hatzidakis A; Rebonato A; Rossi M
    Cardiovasc Intervent Radiol; 2015 Feb; 38(1):13-24. PubMed ID: 25366087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endoscopic imaging in the management of gastroenteropancreatic neuroendocrine tumors.
    Pellicano R; Fagoonee S; Altruda F; Bruno M; Saracco GM; De Angelis C
    Minerva Endocrinol; 2016 Dec; 41(4):490-8. PubMed ID: 27600643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.